Peers: AMPH SUPN TEVA VTRS PRGO

| Held by: IJR VTI IWM VXF AVUV SPSM IJT IWO CALF PJP

Index	RUT	P/E	16.69	EPS (ttm)	2.04	Insider Own	1.68%	Shs Outstand	32.41M	Perf Week	-2.21%
Market Cap	1.11B	Forward P/E	4.48	EPS next Y	7.61	Insider Trans	-15.84%	Shs Float	31.89M	Perf Month	2.49%
Enterprise Value	1.59B	PEG	-	EPS next Q	1.72	Inst Own	122.47%	Short Float	18.62%	Perf Quarter	-24.52%
Income	74.95M	P/S	1.39	EPS this Y	4.04%	Inst Trans	6.90%	Short Ratio	10.85	Perf Half Y	-24.79%
Sales	796.33M	P/B	3.54	EPS next Y	-1.40%	ROA	4.57%	Short Interest	5.94M	Perf YTD	-26.35%
Book/sh	9.64	P/C	2.50	EPS next 5Y	-4.01%	ROE	27.41%	52W High	50.79 -32.86%	Perf Year	13.82%
Cash/sh	13.62	P/FCF	3.35	EPS past 3/5Y	- 17.92%	ROIC	6.20%	52W Low	28.34 20.33%	Perf 3Y	46.54%
Dividend Est.	-	EV/EBITDA	3.81	Sales past 3/5Y	18.94% 20.28%	Gross Margin	60.68%	Volatility	4.05% 4.47%	Perf 5Y	39.75%
Dividend TTM	-	EV/Sales	2.00	EPS Y/Y TTM	73.61%	Oper. Margin	24.16%	ATR (14)	1.51	Perf 10Y	100.71%
Dividend Ex-Date	-	Quick Ratio	1.62	Sales Y/Y TTM	19.88%	Profit Margin	9.41%	RSI (14)	46.25	Recom	1.43
Dividend Gr. 3/5Y	- -	Current Ratio	1.71	EPS Q/Q	442.39%	SMA20	-1.46%	Beta	0.76	Target Price	54.33
Payout	0.00%	Debt/Eq	2.98	Sales Q/Q	8.87%	SMA50	-0.67%	Rel Volume	0.35	Prev Close	33.62
Employees	423	LT Debt/Eq	2.87	Earnings	May 07 BMO	SMA200	-14.02%	Avg Volume	547.10K	Price	34.10
IPO	May 07, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	15.49% 4.91%	Trades		Volume	120,716	Change	1.43%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-09-25	Initiated	Barclays	Overweight	$58
Jan-10-25	Upgrade	Needham	Hold → Buy	$46
Jul-30-24	Upgrade	H.C. Wainwright	Neutral → Buy	$47
Jun-07-24	Upgrade	Jefferies	Hold → Buy	$41 → $44
May-10-24	Downgrade	Piper Sandler	Overweight → Neutral	$39
May-10-24	Downgrade	Needham	Buy → Hold
Jan-04-24	Downgrade	Jefferies	Buy → Hold	$30 → $37
Aug-25-23	Reiterated	Needham	Buy	$35 → $36
May-02-23	Resumed	Jefferies	Buy	$30
Aug-08-22	Downgrade	H.C. Wainwright	Buy → Neutral
Feb-15-22	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$18 → $26
Aug-06-21	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jan-11-21	Reiterated	H.C. Wainwright	Buy	$29 → $33
Jul-14-20	Initiated	BWS Financial	Sell	$8
May-27-20	Initiated	Guggenheim	Neutral
Feb-19-20	Resumed	Jefferies	Buy	$43
Oct-30-19	Reiterated	Needham	Buy	$33 → $25
May-03-19	Resumed	H.C. Wainwright	Buy	$23
Apr-12-19	Resumed	Janney	Buy	$29
Mar-20-19	Initiated	SunTrust	Hold	$22

Show Previous Ratings

May-12-26 07:31AM	Collegium Completes Acquisition of AZSTARYS from Corium Therapeutics (GlobeNewswire)
May-07-26 04:52PM	Collegium Pharmaceutical, Inc. Q1 2026 Earnings Call Summary (Moby) +7.72%
07:54AM	Collegium Pharmaceutical: Q1 Earnings Snapshot (Associated Press)
07:30AM	Collegium Reports First Quarter 2026 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
Apr-23-26 08:00AM	Collegium to Report First Quarter 2026 Financial Results on May 7, 2026 (GlobeNewswire)
08:00AM	Loading…
Apr-08-26 08:00AM	Collegium to Participate in Upcoming Investor Conferences (GlobeNewswire)
Mar-19-26 08:00AM	Collegium to Acquire AZSTARYS from Corium Therapeutics, Strengthening Position in ADHD and Accelerating Growth Trajectory (GlobeNewswire)
Mar-10-26 09:04AM	Collegium Pharmaceutical, Inc. (COLL) Surged Following Record Quarterly Results (Insider Monkey)
Mar-05-26 08:00AM	Collegium to Present New Real-World Data at PainConnect 2026 (GlobeNewswire) -5.88%
Mar-03-26 08:00AM	Paris Hilton Shares Her Experience with JORNAY PM and Launches New 'Embrace Your Sparkle' Campaign with Collegium to Empower the ADHD Community (GlobeNewswire)
Mar-02-26 08:00AM	Collegium to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-27-26 03:20PM	Why Collegium Pharmaceutical (COLL) Stock Is Trading Lower Today (StockStory) -5.77%
Feb-26-26 04:32PM	Collegium Pharmaceutical, Inc. Q4 2025 Earnings Call Summary (Moby)
04:13PM	Collegium Pharmaceutical Inc (COLL) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
12:30PM	Collegium Pharmaceutical (COLL) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
12:15PM	Loading…
12:15PM	Collegium Pharmaceutical (COLL) Q4 Earnings and Revenues Miss Estimates (Zacks)
09:16AM	Collegium Pharmaceutical Q4 Earnings Call Highlights (MarketBeat)
07:53AM	Collegium Pharmaceutical: Q4 Earnings Snapshot (Associated Press Finance)
07:36AM	Collegium Pharmaceutical's (NASDAQ:COLL) Q4 CY2025 Earnings Results: Revenue In Line With Expectations (StockStory)
07:30AM	Collegium Reports Fourth Quarter and Full-Year 2025 Financial Results (GlobeNewswire)
Feb-24-26 10:07PM	Collegium Pharmaceutical (COLL) Q4 Earnings: What To Expect (StockStory)
10:00AM	Rigel Pharmaceuticals (RIGL) Earnings Expected to Grow: Should You Buy? (Zacks)
Feb-23-26 08:00AM	Boston Legacy FC Announces Sensory Room Sponsorship with Collegium Pharmaceutical (GlobeNewswire)
Feb-19-26 10:00AM	Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
09:53AM	Collegium Pharmaceutical to Report Q4 Earnings: What's in the Cards? (Zacks)
08:15AM	Madrigal (MDGL) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
Feb-18-26 04:07AM	Collegium Pharmaceutical, Inc. (COLL) Gains Momentum on Jornay PM, Truist Highlights Robust Pain Portfolio (Insider Monkey)
Feb-12-26 08:00AM	Collegium to Report Fourth Quarter and Full-Year 2025 Financial Results on February 26, 2026 (GlobeNewswire)
Jan-15-26 08:00AM	Collegium to Present Four Real-World Data Posters at APSARD 2026 Annual Conference (GlobeNewswire)
Jan-12-26 09:40AM	Is Collegium Pharmaceutical (COLL) Stock Undervalued Right Now? (Zacks) +5.73%
08:00AM	Loading…
Jan-08-26 08:00AM	Collegium Provides 2026 Financial Guidance and Business Update (GlobeNewswire)
Jan-05-26 09:54AM	Corcept (CORT) Surges 9.8%: Is This an Indication of Further Gains? (Zacks)
Jan-02-26 11:22AM	Here's Why Pediatrix Medical Can Be a Smart Addition to Your Portfolio (Zacks)
Dec-31-25 01:04PM	Why You Should Add Encompass Health to Your Portfolio Now (Zacks)
11:24AM	Here's Why You Should Retain Community Health Stock for Now (Zacks)
Dec-30-25 08:00AM	Collegium Announces the Closing of $980 Million Syndicated Credit Facility (GlobeNewswire)
Dec-28-25 11:01PM	2 Reasons to Avoid COLL and 1 Stock to Buy Instead (StockStory)
Dec-26-25 01:42PM	Here's Why Investors Should Hold Ensign Group Stock for Now (Zacks)
Dec-22-25 09:40AM	Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock? (Zacks)
09:40AM	Are Medical Stocks Lagging Actinium Pharmaceuticals (ATNM) This Year? (Zacks)
Dec-18-25 11:35PM	3 Unpopular Stocks We Find Risky (StockStory)
05:12AM	Best Value Stocks to Buy for Dec. 18 (Zacks)
Dec-14-25 10:31PM	Branded Pharmaceuticals Stocks Q3 Recap: Benchmarking Collegium Pharmaceutical (NASDAQ:COLL) (StockStory)
Dec-11-25 11:34PM	1 Growth Stock Set to Flourishand 2 Facing Challenges (StockStory)
12:51PM	MOH, Aeroflow Team Up to Offer Virtual Diabetes Care in South Carolina (Zacks)
Dec-04-25 09:40AM	Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now? (Zacks)
09:40AM	Is Guardant Health (GH) Stock Outpacing Its Medical Peers This Year? (Zacks)
09:15AM	Collegium Pharmaceutical, Inc. (COLL) Hits Fresh High: Is There Still Room to Run? (Zacks)
Dec-03-25 03:45PM	Ensign Group Expands Foothold in Three U.S. States With Facility Buyouts (Zacks)
Nov-21-25 08:04AM	Why 2025 is a Dynamic and Transformative Year for Collegium (Zacks)
Nov-19-25 08:23AM	Collegium Pharma and Entegris have been highlighted as Zacks Bull and Bear of the Day (Zacks)
04:00AM	Bull of the Day: Collegium Pharmaceutical (COLL) (Zacks)
Nov-18-25 09:40AM	Is Collegium Pharmaceutical (COLL) Stock Undervalued Right Now? (Zacks)
09:40AM	Is Alnylam Pharmaceuticals (ALNY) Stock Outpacing Its Medical Peers This Year? (Zacks)
Nov-13-25 12:36AM	5 Revealing Analyst Questions From Collegium Pharmaceutical's Q3 Earnings Call (StockStory)
Nov-12-25 08:00AM	Collegium to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.60%
Nov-07-25 09:50AM	COLL Q3 Deep Dive: Jornay PM Momentum and Pain Portfolio Drive Upgraded Outlook (StockStory)
Nov-06-25 03:25PM	Why Are Collegium Pharmaceutical (COLL) Shares Soaring Today (StockStory) +13.42%
02:09PM	Collegium Pharmaceutical Inc (COLL) Q3 2025 Earnings Call Highlights: Record Revenue and ... (GuruFocus.com)
09:30AM	Here's What Key Metrics Tell Us About Collegium Pharmaceutical (COLL) Q3 Earnings (Zacks)
08:50AM	Collegium Pharmaceutical (COLL) Q3 Earnings and Revenues Beat Estimates (Zacks)
08:09AM	Collegium Pharmaceutical (NASDAQ:COLL) Delivers Impressive Q3, Stock Jumps 12.1% (StockStory)
07:47AM	Collegium Pharmaceutical: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Collegium Reports Third Quarter 2025 Financial Results; Raises 2025 Guidance (GlobeNewswire)
Nov-04-25 10:22PM	Earnings To Watch: Collegium Pharmaceutical (COLL) Reports Q3 Results Tomorrow (StockStory)
Oct-31-25 11:18AM	3 Explosive Stocks With High Short Interest (24/7 Wall St.)
Oct-30-25 10:00AM	Collegium Pharmaceutical (COLL) Earnings Expected to Grow: Should You Buy? (Zacks)
Oct-29-25 08:00AM	Paris Hilton Collaborates with Collegium Pharmaceutical to Share Her Personal ADHD Journey and Experience with Treatment (GlobeNewswire)
Oct-23-25 08:00AM	Collegium to Report Third Quarter 2025 Financial Results on November 6, 2025 (GlobeNewswire)
12:02AM	Collegium Pharmaceutical (COLL): Buy, Sell, or Hold Post Q2 Earnings? (StockStory)
Oct-22-25 08:00AM	Collegium Announces Poster Presentations at the American Academy of Child & Adolescent Psychiatry and Neuroscience Education Institute Conferences (GlobeNewswire)
Oct-13-25 08:00AM	Collegium to Celebrate 10-Year Anniversary with Nasdaq Opening Bell Ringing (GlobeNewswire)
Oct-08-25 11:25AM	Collegium Pharmaceutical, Inc. (COLL): A Bull Case Theory (Insider Monkey)
Oct-06-25 09:51AM	ESPR Settles Nexletol/Nexlizet Patent Litigation With RDY, Stock Up (Zacks)
Sep-25-25 07:19PM	Don't Overlook These 2 Highly Ranked Medical Stocks: COLL, MASI (Zacks)
12:00PM	All You Need to Know About Collegium Pharmaceutical (COLL) Rating Upgrade to Strong Buy (Zacks)
Sep-24-25 11:31PM	Branded Pharmaceuticals Stocks Q2 Highlights: Collegium Pharmaceutical (NASDAQ:COLL) (StockStory)
Sep-23-25 09:40AM	Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock? (Zacks)
09:40AM	Are Medical Stocks Lagging Argenx (ARGX) This Year? (Zacks)
Sep-02-25 04:07AM	Collegium Pharmaceutical, Inc. (COLL) to Present 9 Pain Studies at PAINWeek 2025 (Insider Monkey)
Aug-29-25 05:07AM	Collegium Pharmaceutical, Inc. (COLL) Highlights Real-World Evidence at PAINWeek 2025 (Insider Monkey)
Aug-28-25 08:00AM	Collegium to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-25-25 08:00AM	Collegium to Present Nine Real-World Data Posters at PAINWeek 2025 Annual Meeting (GlobeNewswire)
Aug-14-25 01:34AM	The 5 Most Interesting Analyst Questions From Collegium Pharmaceutical's Q2 Earnings Call (StockStory)
Aug-12-25 03:25AM	COLL Q2 Deep Dive: Jornay Expansion Drives Revenue Guidance Increase, Margins Face Investment Pressure (StockStory)
Aug-11-25 09:33AM	Arm initiated, Adobe downgraded: Wall Street's top analyst calls (The Fly)
Aug-07-25 02:53PM	Collegium Pharmaceutical (NASDAQ:COLL) Exceeds Q2 Expectations, Stock Jumps 10.2% (StockStory) +10.72%
09:30AM	Compared to Estimates, Collegium Pharmaceutical (COLL) Q2 Earnings: A Look at Key Metrics (Zacks)
08:50AM	Collegium Pharmaceutical (COLL) Q2 Earnings and Revenues Surpass Estimates (Zacks)
07:49AM	Collegium Pharmaceutical: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	Collegium Reports Second Quarter 2025 Financial Results; Raises 2025 Outlook (GlobeNewswire)
Aug-06-25 05:50PM	Inotiv, Inc. (NOTV) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
Aug-05-25 11:11PM	Collegium Pharmaceutical (COLL) Q2 Earnings: What To Expect (StockStory)
10:00AM	Zevra Therapeutics (ZVRA) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Jul-31-25 10:00AM	Collegium Pharmaceutical (COLL) Q2 Earnings Preview: What's in the Cards? (Zacks)
Jul-28-25 12:01AM	3 Reasons to Avoid COLL and 1 Stock to Buy Instead (StockStory)
Jul-25-25 09:55AM	Wall Street Analysts See a 33.91% Upside in Collegium Pharmaceutical (COLL): Can the Stock Really Move This High? (Zacks)
09:40AM	Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now? (Zacks)
Jul-24-25 08:00AM	Collegium to Report Second Quarter 2025 Financial Results on August 7, 2025 (GlobeNewswire)
Jul-10-25 04:09PM	5 Hot Stocks With Summer Buybacks You Can Cash In On (MarketBeat)

Collegium Pharmaceutical, Inc. is a pharmaceutical company, which engages in development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR, Belbuca, and Symproic. The company was founded by Michael Thomas Heffernan in April 2002 and is headquartered in Stoughton, MA.

CEOMr. Vikram Karnani

Executive VP & CFOMs. Colleen Tupper

Executive VPMr. David Dieter

Executive VP & Chief Commercial OfficerMr. Scott Dreyer

M.D.Dr. Thomas B. Smith FAAFP

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Freund John Gordon	Director	May 15 '26	Option Exercise	16.49	8,700	143,463	88,099	May 18 04:15 PM
Freund John Gordon	Director	May 15 '26	Sale	34.54	4,127	142,547	83,972	May 18 04:15 PM
Freund John Gordon	Director	May 18 '26	Proposed Sale	34.05	30	1,022		May 18 04:07 PM
Lurker Nancy	Director	May 13 '26	Sale	35.97	4,500	161,861	18,017	May 15 04:05 PM
Freund John Gordon	Director	May 15 '26	Proposed Sale	34.54	4,127	142,547		May 15 10:51 AM
BOHLIN GAREN G	Director	May 11 '26	Option Exercise	16.49	8,700	143,463	70,959	May 13 04:05 PM
BOHLIN GAREN G	Director	May 11 '26	Sale	37.18	8,700	323,491	62,259	May 13 04:05 PM
Lurker Nancy	Director	May 13 '26	Proposed Sale	35.97	4,500	161,861		May 13 12:09 PM
BOHLIN GAREN G	Director	May 11 '26	Proposed Sale	37.18	8,700	323,491		May 11 11:38 AM
Dieter David	EVP & General Counsel	Mar 18 '26	Sale	34.92	13,976	488,099	77,071	Mar 20 05:14 PM
Dieter David	Officer	Mar 18 '26	Proposed Sale	34.92	13,976	488,099		Mar 18 04:10 PM
Dieter David	Officer	Mar 09 '26	Proposed Sale	36.65	6,224	228,110		Mar 09 10:39 AM
Dreyer Scott	EVP & Chief Commercial Officer	Mar 03 '26	Sale	40.41	49,976	2,019,437	71,770	Mar 05 04:29 PM
Dreyer Scott	Officer	Mar 03 '26	Proposed Sale	40.41	49,976	2,019,439		Mar 03 04:10 PM
RITA BALICE-GORDON	DIRECTOR	Dec 05 '25	Proposed Sale	47.03	3,650	171,673		Dec 17 04:01 PM
Dreyer Scott	EVP & Chief Commercial Officer	Dec 08 '25	Option Exercise	15.90	17,600	279,840	121,213	Dec 10 04:32 PM
Dreyer Scott	EVP & Chief Commercial Officer	Dec 08 '25	Sale	48.17	17,600	847,855	103,613	Dec 10 04:32 PM
Balice-Gordon Rita J.	Director	Dec 05 '25	Sale	47.03	3,650	171,673	52,629	Dec 09 04:22 PM
Dreyer Scott	Officer	Dec 08 '25	Proposed Sale	48.17	17,600	847,855		Dec 08 04:11 PM
Fallon John A.	Director	Nov 12 '25	Option Exercise	12.41	34,853	432,578	99,487	Nov 14 04:10 PM
Fallon John A.	Director	Nov 12 '25	Sale	47.21	34,853	1,645,536	64,634	Nov 14 04:10 PM
Fallon John A.	Director	Nov 12 '25	Proposed Sale	47.21	34,853	1,645,536		Nov 12 04:29 PM
Tupper Colleen	EVP & Chief Financial Officer	Nov 06 '25	Sale	40.53	30,000	1,215,753	126,667	Nov 07 04:23 PM
Tupper Colleen	Officer	Nov 06 '25	Proposed Sale	40.53	30,000	1,215,754		Nov 06 04:11 PM
Smith Thomas B	EVP and Chief Medical Officer	Aug 29 '25	Sale	38.42	17,478	671,576	70,264	Sep 03 04:56 PM
Smith Thomas B	Officer	Aug 29 '25	Proposed Sale	38.42	17,478	671,576		Aug 29 02:12 PM
Dreyer Scott	EVP & Chief Commercial Officer	Aug 18 '25	Option Exercise	21.34	16,389	349,741	120,002	Aug 20 04:57 PM
Dreyer Scott	EVP & Chief Commercial Officer	Aug 18 '25	Sale	38.21	16,389	626,171	103,613	Aug 20 04:57 PM
SANTINI GINO	Director	Aug 15 '25	Option Exercise	13.45	15,000	201,750	100,447	Aug 19 05:10 PM
SANTINI GINO	Director	Aug 15 '25	Sale	37.19	5,405	201,018	95,042	Aug 19 05:10 PM
Dreyer Scott	Officer	Aug 18 '25	Proposed Sale	38.21	16,389	626,170		Aug 18 04:50 PM
Dreyer Scott	EVP & Chief Commercial Officer	Aug 13 '25	Option Exercise	21.34	4,861	103,734	108,474	Aug 15 05:08 PM
Dreyer Scott	EVP & Chief Commercial Officer	Aug 13 '25	Sale	38.03	4,861	184,881	103,613	Aug 15 05:08 PM
Rubric Capital Management LP	10% Owner	Aug 13 '25	Sale	37.85	25,000	946,250	3,132,743	Aug 15 04:12 PM
SANTINI GINO	Director	Aug 15 '25	Proposed Sale	37.19	5,405	201,019		Aug 15 12:34 PM
Dreyer Scott	Officer	Aug 13 '25	Proposed Sale	38.03	4,861	184,881		Aug 13 04:31 PM
Freund John Gordon	Director	Aug 08 '25	Sale	34.36	11,659	400,641	23,129	Aug 12 05:18 PM
Heffernan Michael Thomas	Former Director	Jul 09 '25	Proposed Sale	32.17	10,328	332,269		Jul 09 04:10 PM
Heffernan Michael Thomas	Former Director	Jul 08 '25	Proposed Sale	31.38	790	24,792		Jul 08 04:19 PM
Heffernan Michael Thomas	Former Director	Jul 07 '25	Proposed Sale	31.25	14,210	444,062		Jul 07 04:43 PM
Heffernan Michael Thomas	Former Director	Jul 02 '25	Proposed Sale	30.30	25,000	757,380		Jul 02 04:50 PM
Melincoff Gwen A	Former Director	Jul 02 '25	Proposed Sale	30.29	47,082	1,425,971		Jul 02 04:35 PM
Freund John Gordon	Director	Jun 09 '25	Option Exercise	13.45	15,000	201,750	77,259	Jun 11 05:04 PM
Freund John Gordon	Director	Jun 09 '25	Sale	30.62	6,601	202,149	70,658	Jun 11 05:04 PM
Freund John Gordon	Director	Jun 09 '25	Proposed Sale	30.62	6,601	202,148		Jun 09 01:02 PM

Open in Screener

EYPT

EyePoint Inc

May 20 • 01:29PM ET

12.65

+0.83 7.00 %

Healthcare • Biotechnology • USA • Small • NASD

Peers: OCUL OMER RGNX OCGN OPK

| Held by: VTI IWM VXF IWN VTWO XPH SCHA PINK VHT IWC

Index	RUT	P/E	-	EPS (ttm)	-3.50	Insider Own	12.73%	Shs Outstand	83.45M	Perf Week	-5.83%
Market Cap	1.06B	Forward P/E	-	EPS next Y	-2.83	Insider Trans	-1.10%	Shs Float	73.17M	Perf Month	-10.37%
Enterprise Value	860.11M	PEG	-	EPS next Q	-0.92	Inst Own	101.77%	Short Float	19.39%	Perf Quarter	-13.97%
Income	-271.60M	P/S	139.15	EPS this Y	-10.31%	Inst Trans	10.64%	Short Ratio	13.13	Perf Half Y	-3.71%
Sales	7.62M	P/B	4.58	EPS next Y	19.19%	ROA	-83.47%	Short Interest	14.19M	Perf YTD	-30.78%
Book/sh	2.76	P/C	4.76	EPS next 5Y	23.53%	ROE	-102.71%	52W High	19.11 -33.82%	Perf Year	103.66%
Cash/sh	2.65	P/FCF	-	EPS past 3/5Y	-4.94% 2.18%	ROIC	-108.34%	52W Low	5.45 131.84%	Perf 3Y	94.57%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-8.83% -1.85%	Gross Margin	56.51%	Volatility	5.08% 5.53%	Perf 5Y	38.07%
Dividend TTM	-	EV/Sales	112.88	EPS Y/Y TTM	-45.44%	Oper. Margin	-3700.89%	ATR (14)	0.75	Perf 10Y	-55.78%
Dividend Ex-Date	-	Quick Ratio	6.63	Sales Y/Y TTM	-86.41%	Profit Margin	-3566.63%	RSI (14)	43.10	Recom	1.08
Dividend Gr. 3/5Y	- -	Current Ratio	6.66	EPS Q/Q	-52.27%	SMA20	-4.51%	Beta	1.75	Target Price	37.00
Payout	-	Debt/Eq	0.10	Sales Q/Q	-97.15%	SMA50	-6.48%	Rel Volume	0.63	Prev Close	11.82
Employees	214	LT Debt/Eq	0.09	Earnings	May 06 BMO	SMA200	-9.33%	Avg Volume	1.08M	Price	12.65
IPO	Jan 27, 2005	Option/Short	Yes / Yes	EPS/Sales Surpr.	-22.92% 97.28%	Trades		Volume	427,210	Change	7.00%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-17-25	Initiated	RBC Capital Mkts	Outperform	$28
Jan-07-25	Initiated	Citigroup	Buy	$33
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Aug-28-24	Initiated	Jefferies	Buy	$15
Jan-22-24	Initiated	JP Morgan	Overweight	$35
Nov-02-23	Initiated	Mizuho	Buy	$20
Apr-21-23	Initiated	Robert W. Baird	Outperform	$33
Jul-07-22	Initiated	Chardan Capital Markets	Buy	$21
Mar-01-21	Initiated	Cowen	Outperform	$25
Jan-28-21	Initiated	Cantor Fitzgerald	Overweight	$22
Apr-06-20	Downgrade	B. Riley FBR	Buy → Neutral	$4 → $1
Nov-04-19	Resumed	Laidlaw	Buy	$5
Sep-12-19	Initiated	Guggenheim	Buy

Show Previous Ratings

May-19-26 07:00AM	EyePoint Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
May-18-26 07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) -5.26%
May-14-26 07:00AM	EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU, Building Confidence Ahead of Mid-2026 Topline Data (GlobeNewswire)
May-07-26 08:30AM	EyePoint Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary (Moby)
May-06-26 07:21AM	EyePoint: Q1 Earnings Snapshot (Associated Press)
07:00AM	Loading…
07:00AM	EyePoint Reports First Quarter 2026 Financial Results and Highlights Recent Corporate Developments (GlobeNewswire)
Apr-29-26 07:00AM	EyePoint to Report First Quarter 2026 Financial Results on May 6, 2026 (GlobeNewswire)
Apr-16-26 04:01PM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-20-26 06:12PM	EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug (Reuters)
Mar-16-26 07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-04-26 04:03PM	EyePoint Inc (EYPT) Q4 2025 Earnings Call Highlights: Navigating Revenue Decline Amid Promising ... (GuruFocus.com) -12.44%
12:36PM	EyePoint Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary (Moby)
10:36AM	Eyepoint Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat)
08:20AM	EyePoint (EYPT) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:23AM	EyePoint: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Loading…
07:00AM	EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments (GlobeNewswire)
Mar-02-26 07:00AM	EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU for the Treatment of Diabetic Macular Edema (GlobeNewswire)
Feb-26-26 12:15PM	Novavax (NVAX) Beats Q4 Earnings and Revenue Estimates (Zacks)
Feb-25-26 07:00AM	EyePoint to Report Fourth Quarter and Full-Year 2025 Financial Results on March 4, 2026 (GlobeNewswire)
Feb-24-26 07:00AM	EyePoint Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Feb-18-26 07:58AM	EyePoint (EYPT) Surges 15.2%: Is This an Indication of Further Gains? (Zacks)
07:00AM	EyePoint Appoints Michael Campbell as Chief Commercial Officer (GlobeNewswire)
Feb-17-26 08:30AM	Ocular Therapeutix stock news: Why positive data led to a 25% drop (Investing.com) +15.22%
07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-16-26 09:40AM	Wall Street Thinks These 4 Biotech Stocks Will DoubleAt LeastThis Year (24/7 Wall St.)
Feb-13-26 05:12PM	EyePoint Pharmaceuticals Teases Mid-2026 DURAVYU Wet AMD Data, Starts Phase III DME Program (MarketBeat) +15.22%
Feb-05-26 07:00AM	EyePoint to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire)
Jan-16-26 07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-07-26 07:00AM	EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026 (GlobeNewswire)
Dec-22-25 12:00PM	EyePoint (EYPT) Is Up 9.01% in One Week: What You Should Know (Zacks) +8.15%
08:10AM	Loading…
08:10AM	3 Biotech Stocks Wall Street Analysts Are Bullish on for 2026 (Zacks)
Dec-20-25 12:00PM	The 2 Riskiest Stocks Investors Are Betting On With Over 300% Upside (Barchart)
Dec-17-25 07:00AM	EyePoint to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-16-25 07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-19-25 07:00AM	EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU in Wet Age-Related Macular Degeneration (GlobeNewswire)
Nov-17-25 07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) +13.43%
Nov-07-25 04:00AM	EyePoint Pharmaceuticals Inc (EYPT) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
Nov-05-25 08:15AM	EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -11.10%
07:22AM	EyePoint Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	EyePoint Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Developments (GlobeNewswire)
Nov-04-25 08:06AM	EyePoint Pharmaceuticals Inc (EYPT) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Nov-03-25 07:00AM	EyePoint Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Oct-29-25 07:00AM	EyePoint to Report Third Quarter 2025 Financial Results on November 5, 2025 (GlobeNewswire)
Oct-16-25 07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-14-25 10:43PM	EyePoint Announces Pricing of Public Offering (GlobeNewswire) -10.87%
04:35PM	EyePoint Announces Proposed Public Offering of Common Stock (GlobeNewswire)
04:01PM	EyePoint Announces Pivotal Phase 3 Program Initiation for DURAVYU in Diabetic Macular Edema (GlobeNewswire)
Sep-25-25 09:29AM	Nurix Therapeutics (NRIX) Soars 5.6%: Is Further Upside Left in the Stock? (Zacks) -6.32%
Sep-23-25 01:13PM	Biotech Stocks Rally. 3 Favorite Plays From the Charts. (Barrons.com)
Sep-16-25 07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-26-25 07:00AM	EyePoint Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Aug-18-25 04:01PM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-06-25 08:30AM	EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:30AM	EyePoint to Present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference (GlobeNewswire)
07:26AM	EyePoint Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	EyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Developments (GlobeNewswire)
Aug-05-25 10:08AM	EyePoint Pharmaceuticals Inc (EYPT) Q2 2025 Earnings Report Preview: What To Expect (GuruFocus.com) +8.25%
Jul-30-25 06:00PM	Guardant Health (GH) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
07:00AM	EyePoint to Report Second Quarter 2025 Financial Results on August 6, 2025 (GlobeNewswire)
05:57AM	Enrolment concludes in EyePoints Phase III programme of Duravyu for wet AMD (Clinical Trials Arena)
Jul-29-25 07:00AM	EyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU in Wet Age-Related Macular Degeneration (GlobeNewswire)
Jul-16-25 07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-16-25 07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-06-25 11:54AM	Breakout Momentum Plays You May Not Know About (MarketBeat) +8.36%
May-28-25 04:01PM	EyePoint Announces Participation at Upcoming Investor Conferences (GlobeNewswire) +18.12%
May-27-25 07:00AM	EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU for Treatment of Wet Age-Related Macular Degeneration (GlobeNewswire)
May-16-25 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) +7.17%
May-13-25 07:00AM	EyePoint Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
May-07-25 02:49PM	Eyepoint projects DURAVYU Phase 3 enrollment completion by H2 2025 amid strong clinical trial momentum (Seeking Alpha)
02:49PM	EyePoint Pharmaceuticals, Inc. (EYPT) Q1 2025 Earnings Call Transcript (Seeking Alpha)
09:30AM	EyePoint Pharmaceuticals (EYPT) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
08:25AM	EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:22AM	EyePoint Pharmaceuticals: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	EyePoint Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Developments (GlobeNewswire)
Apr-30-25 07:00AM	EyePoint to Report First Quarter 2025 Financial Results on May 7, 2025 (GlobeNewswire)
Apr-16-25 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-27-25 07:00AM	EyePoint to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference (GlobeNewswire)
Mar-17-25 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-06-25 02:14AM	Q4 2024 EyePoint Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
02:06AM	EyePoint Pharmaceuticals Inc (EYPT) Q4 2024 Earnings Call Highlights: Navigating Challenges ... (GuruFocus.com)
Mar-05-25 09:30AM	EyePoint Pharmaceuticals (EYPT) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks) +8.22%
08:25AM	EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:34AM	EyePoint Pharmaceuticals: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	EyePoint Reports Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Developments (GlobeNewswire)
Mar-04-25 07:17AM	Earnings To Watch: EyePoint Pharmaceuticals Inc (EYPT) Reports Q4 2024 Result (GuruFocus.com) +6.29%
07:00AM	EyePoint Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Feb-26-25 07:00AM	EyePoint to Report Fourth Quarter and Full-Year 2024 Financial Results on March 5, 2025 (GlobeNewswire)
Feb-25-25 07:00AM	EyePoint to Present Corporate Update at TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Feb-17-25 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-05-25 07:00AM	EyePoint Announces Positive Six-Month Results for the Phase 2 VERONA Clinical Trial of DURAVYU for Diabetic Macular Edema Meeting Primary and Secondary Endpoints (GlobeNewswire)
Jan-30-25 07:00AM	EyePoint to Present at Guggenheim SMID Cap Biotech Conference (GlobeNewswire)
Jan-16-25 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) -5.46%
Jan-13-25 07:00AM	EyePoint Provides Company Update and Anticipated Development Milestones for 2025 (GlobeNewswire) -7.07%
Jan-08-25 07:00AM	EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D., FASRS to Board of Directors (GlobeNewswire)
Dec-17-24 07:25AM	EyePoint reports inducement grants under NASDAQ listing rule (TipRanks) +5.39%
07:00AM	EyePoint to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-16-24 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-05-24 07:06AM	EyePoint doses first patient in second Phase 3 LUCIA clinical trial (TipRanks)
Dec-04-24 07:00AM	EyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU for the Treatment of Wet Age-Related Macular Degeneration (GlobeNewswire)
Nov-18-24 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) -6.43%

EyePoint, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.

PresidentDr. Jay S. Duker M.D.

Executive VP & CFOMr. George O. Elston CPA

Ph.D.Dr. Ramiro Ribeiro M.D.

Chief Scientific OfficerDr. Marcia Sellos-Moura Ph.D.

Chief Legal Officer & Company SecretaryMr. Ron I. Honig Esq.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Ribeiro Ramiro	Chief Medical Officer	Apr 17 '26	Option Exercise	8.26	2,437	20,130	2,437	Apr 20 04:07 PM
Ribeiro Ramiro	Chief Medical Officer	Apr 17 '26	Sale	15.00	2,437	36,555	0	Apr 20 04:07 PM
Ramiro Ribeiro	Officer	Apr 17 '26	Proposed Sale	14.81	9,750	144,398		Apr 17 04:36 PM
Duker Jay S.	President and CEO	Mar 16 '26	Buy	13.15	1,500	19,724	100,665	Mar 16 04:12 PM
Ribeiro Ramiro	Chief Medical Officer	Mar 04 '26	Option Exercise	8.26	2,438	20,138	2,438	Mar 05 04:02 PM
Ribeiro Ramiro	Chief Medical Officer	Mar 04 '26	Sale	17.87	2,438	43,572	0	Mar 05 04:02 PM
Ribeiro Ramiro	Chief Medical Officer	Feb 17 '26	Option Exercise	8.26	2,437	20,130	2,437	Feb 18 04:07 PM
Ribeiro Ramiro	Chief Medical Officer	Feb 17 '26	Sale	15.00	2,437	36,555	0	Feb 18 04:07 PM
Lurker Nancy	Director	Jan 06 '26	Option Exercise	0.00	75,133	0	294,346	Jan 07 04:13 PM
Duker Jay S.	President and CEO	Jan 06 '26	Option Exercise	0.00	20,793	0	87,806	Jan 07 04:12 PM
Elston George	Chief Financial Officer	Jan 06 '26	Option Exercise	0.00	15,285	0	96,339	Jan 07 04:12 PM
Ribeiro Ramiro	Chief Medical Officer	Jan 05 '26	Option Exercise	8.26	29,250	241,605	42,544	Jan 07 04:07 PM
Ribeiro Ramiro	Chief Medical Officer	Jan 05 '26	Sale	17.10	42,544	727,319	0	Jan 07 04:07 PM
Ribeiro Ramiro	Chief Medical Officer	Jan 03 '26	Option Exercise	0.00	19,667	0	19,667	Jan 06 04:47 PM
Duker Jay S.	President and CEO	Jan 05 '26	Option Exercise	0.00	30,000	0	81,518	Jan 06 04:10 PM
Duker Jay S.	President and CEO	Jan 03 '26	Option Exercise	0.00	65,000	0	74,965	Jan 06 04:10 PM
Elston George	Chief Financial Officer	Jan 05 '26	Option Exercise	0.00	15,000	0	85,457	Jan 06 04:10 PM
Elston George	Chief Financial Officer	Jan 03 '26	Option Exercise	0.00	19,667	0	76,781	Jan 06 04:10 PM
Lurker Nancy	Director	Jan 05 '26	Option Exercise	0.00	12,666	0	219,213	Jan 06 04:07 PM
Ramiro Ribeiro	Officer	Jan 05 '26	Proposed Sale	17.48	53,792	940,284		Jan 05 04:42 PM
Cormorant Asset Management, LP	Former 10% Owner	Dec 04 '25	Sale	15.70	60,000	942,240	8,265,000	Dec 08 04:03 PM
Lurker Nancy	Director	Dec 04 '25	Sale	15.11	9,300	140,477	206,547	Dec 05 04:06 PM
Lurker Nancy	Officer	Dec 04 '25	Proposed Sale	15.11	9,300	140,477		Dec 04 10:24 AM
Lurker Nancy	Director	Nov 28 '25	Sale	14.95	500	7,475	215,847	Dec 01 04:09 PM
Lurker Nancy	Director	Nov 26 '25	Sale	14.95	200	2,990	216,347	Dec 01 04:09 PM
Lurker Nancy	Officer	Nov 28 '25	Proposed Sale	14.95	500	7,475		Nov 28 01:23 PM
Lurker Nancy	Officer	Nov 26 '25	Proposed Sale	14.95	200	2,990		Nov 26 04:09 PM
Ribeiro Ramiro	Chief Medical Officer	Nov 11 '25	Sale	11.61	2,722	31,602	0	Nov 12 04:03 PM
Ramiro Ribeiro	Officer	Nov 11 '25	Proposed Sale	11.35	2,722	30,895		Nov 12 06:55 AM
Zaderej Karen L.	Director	Jul 11 '25	Option Exercise	0.00	2,000	0	38,500	Jul 11 04:07 PM
Lurker Nancy	Director	Jul 10 '25	Option Exercise	0.00	11,111	0	216,547	Jul 11 04:06 PM
Duker Jay S.	President and CEO	Jul 10 '25	Option Exercise	0.00	16,667	0	17,653	Jul 11 04:06 PM
Elston George	Chief Financial Officer	May 25 '25	Option Exercise	0.00	7,500	0	83,050	May 27 04:08 PM

COLL

Collegium Pharmaceutical Inc

EYPT

EyePoint Inc

Upgrade your Finviz experience